We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+14.34%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$29.7M
AUM Growth
-$663K
Cap. Flow
-$3.72M
Cap. Flow %
-12.53%
Top 10 Hldgs %
82.03%
Holding
19
New
1
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
YARW
Yarrow Bioscience
YARW
+$352K
2
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$338K

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$2.23M
2
SPXU icon
ProShares UltraPro Short S&P 500
SPXU
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 84.01%
2 Miscellaneous 12.66%
3 Consumer Staples 3.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$456B
$3.75M 12.63%
35,000
– –
GSK icon
2
GSK
GSK
$101B
$3.68M 12.4%
80,000
– –
YARW
3
Yarrow Bioscience
YARW
$104M
$3.16M 10.65%
556
+56
+11% +$352K
GILD icon
4
Gilead Sciences
GILD
$185B
$2.91M 9.81%
50,000
– –
TYME
5
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$2.65M 8.94%
2,175,000
– –
ATRS
6
DELISTED
Antares Pharma, Inc.
ATRS
$2M 6.72%
500,000
– –
MCK icon
7
McKesson
MCK
$104B
$1.74M 5.86%
10,000
– –
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$16.3B
$1.65M 5.56%
10,000
-15,000
-60% -$2.23M
AMRN
9
CALL
Amarin Corp
AMRN
$299M
$1.47M 4.94%
15,000
+10,000
+200% +$964K
CAH icon
10
Cardinal Health
CAH
$54.7B
$1.34M 4.51%
25,000
– –
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$1.2M 4.04%
250,000
– –
MRNA icon
12
PUT
Moderna
MRNA
$57B
$1.04M 3.52%
10,000
– –
GNLN icon
13
Greenlane Holdings
GNLN
$1.95M
– –
0
– –
VIXY icon
14
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$687K 2.31%
625
+312
+100% +$415K
NVAX icon
15
PUT
Novavax
NVAX
$1.49B
$558K 1.88%
5,000
– –
ADMS
16
DELISTED
Adamas Pharmaceuticals
ADMS
$433K 1.46%
100,000
– –
GMDA
17
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$420K 1.42%
+50,000
New +$338K
SPXU icon
18
CALL
ProShares UltraPro Short S&P 500
SPXU
$384M
– –
-1,000
Closed -$870K
SPXU icon
19
ProShares UltraPro Short S&P 500
SPXU
$384M
– –
-2,500
Closed -$2.17M

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Healthcare Value Capital held 19 positions worth $29.7M, down 2.2% from $30.3M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Healthcare Value Capital withdrew a net $3.72M in Q4 2020, closing 2 positions and reducing 1 holding. Its most notable exit was ProShares UltraPro Short S&P 500, an estimated $2.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Healthcare Value Capital opened a new position in Gamida Cell Ltd. Ordinary Shares worth $420K.

  • Healthcare Value Capital's largest Q4 2020 buy was Gamida Cell Ltd. Ordinary Shares: 50,000 shares worth $420K.
  • Healthcare Value Capital added most to Yarrow Bioscience in Q4 2020, an estimated $352K increase.
  • Healthcare Value Capital's biggest Q4 2020 reduction was Jazz Pharmaceuticals, cutting an estimated $2.23M.
  • Healthcare Value Capital fully exited ProShares UltraPro Short S&P 500 in Q4 2020, selling an estimated $2.17M.
  • Healthcare Value Capital's ten largest holdings make up 82% of its $29.7M portfolio in Q4 2020.
  • Healthcare Value Capital opened 1 new position and closed 2 in Q4 2020.
  • Healthcare Value Capital's portfolio value fell 2.2% quarter-over-quarter to $29.7M.

Based on Healthcare Value Capital's 13F filing for Q4 2020, filed 16 Feb 2021.